

## HEDIS® Measurement Year 2023 HMO Annual Report

Measure Name	BCBSIL HMO HEDIS Rate	Quality Compass National Average (excluding PPOs and EPOs)
<b>Effectiveness of Care: Prevention and Screening</b>		
• Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) - BMI Percentile (Total)	87%	73%
• Childhood Immunization Status (CIS) - Combination 10	57%	51%
• Immunizations for Adolescents (IMA) - Combination 2	43%	35%
• Breast Cancer Screening (BCS-E)	79%	75%
• Cervical Cancer Screening (CCS)	77%	73%
• Colorectal Cancer Screening (COL) - Total	64%	60%
• Chlamydia Screening in Women (CHL) - Total	48%	49%
<b>Effectiveness of Care: Respiratory Conditions</b>		
• Appropriate Testing for Pharyngitis (CWP) - Total	87%	76%
• Pharmacotherapy Management of COPD Exacerbation (PCE)		
○ Systemic Corticosteroid	68%	77%
○ Bronchodilator	81%	82%
• Asthma Medication Ratio (AMR) - Total	87%	82%
<b>Effectiveness of Care: Cardiovascular Conditions</b>		
• Controlling High Blood Pressure (CBP)	76%	64%
• Statin Therapy for Patients with Cardiovascular Disease (SPC)		
○ Received Statin Therapy (Total)	86%	82%
○ Statin Adherence 80% (Total)	81%	78%
<b>Effectiveness of Care: Diabetes</b>		
• Hemoglobin A1c Control for Patients With Diabetes (HBD)		
○ HbA1c Control (<8%)	71%	64%
○ Poor HbA1c Control	18%	28%
• Statin Therapy for Patients with Diabetes (SPD)		
○ Received Statin Therapy	69%	65%
○ Statin Adherence 80%	71%	73%
<b>Effectiveness of Care: Behavioral Health</b>		
• Antidepressant Medication Management (AMM) - Effective Continuation Phase Treatment	59%	59%
• Follow-Up Care for Children Prescribed ADHD Medications (ADD) - Continuation & Maintenance Phase	48%	49%
• Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Blood Glucose and Cholesterol Testing (Total)	37%	37%
• Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)	66%	66%
• Follow-Up After Hospitalization for Mental Illness (FUH) - 7 days (Total)	42%	49%
• Follow-Up After Emergency Department Visit for Mental Illness (FUM) - 7 days (Total)	47%	48%

## HEDIS® Measurement Year 2023 HMO Annual Report

(Continued from Page 1)

Measure Name	BCBSIL HMO HEDIS Rate	Quality Compass National Average (excluding PPOs and EPOs)
<b>Effectiveness of Care: Behavioral Health</b>		
• Pharmacotherapy for Opioid Use Disorder (POD) - Total	16%	30%
• Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) - 7 Days (Total)	29%	42%
• Follow-Up After Emergency Department Visit for Substance Use (FUA) - 7 days (Total)	24%	22%
<b>Effectiveness of Care: Overuse/Appropriateness</b>		
• Appropriate Treatment for Upper Respiratory Infection (URI) - Total	84%	82%
• Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB) - Total	55%	51%
• Appropriate Use of Imaging Studies for Low Back Pain (LBP)	66%	75%
• Avoiding Opioids at High Dosage (HDO)	98%	96%
• Avoiding Opioids from Multiple Prescribers and Multiple Pharmacies (UOP)	99%	99%
• Avoiding Potentially Risky Continued Opioid Use (COU) >=31 Days (Total)	98%	98%
<b>Access/Availability of Care:</b>		
• Initiation and Engagement of Substance Use Disorder Treatment (IET) - Engagement of SUD treatment - Total	11%	13%
• Prenatal and Postpartum Care (PPC)		
○ Timeliness of Prenatal Care	93%	83%
○ Postpartum Care	94%	84%
• Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) - Total	67%	62%

Data based on Measurement Year (MY) 2023.

Results are rounded to the nearest percentage.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).